CN112512524A - 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法 - Google Patents

给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法 Download PDF

Info

Publication number
CN112512524A
CN112512524A CN201980046617.8A CN201980046617A CN112512524A CN 112512524 A CN112512524 A CN 112512524A CN 201980046617 A CN201980046617 A CN 201980046617A CN 112512524 A CN112512524 A CN 112512524A
Authority
CN
China
Prior art keywords
patient
methyl
hydroxyethyl
ethoxy
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980046617.8A
Other languages
English (en)
Chinese (zh)
Inventor
M·马蒂内尔皮德蒙特
M·P·皮兹库塔拉朗扎
G·皮纳拉格纳
U·美亚
A·柏伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minoryx Therapeutics SL
Original Assignee
Minoryx Therapeutics SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics SL filed Critical Minoryx Therapeutics SL
Publication of CN112512524A publication Critical patent/CN112512524A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980046617.8A 2018-06-06 2019-06-06 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法 Pending CN112512524A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18382398.8 2018-06-06
EP18382398 2018-06-06
PCT/IB2019/054743 WO2019234689A1 (en) 2018-06-06 2019-06-06 Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione

Publications (1)

Publication Number Publication Date
CN112512524A true CN112512524A (zh) 2021-03-16

Family

ID=62716009

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980046617.8A Pending CN112512524A (zh) 2018-06-06 2019-06-06 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法

Country Status (14)

Country Link
US (1) US20210308113A1 (https=)
EP (1) EP3801516A1 (https=)
JP (1) JP7549344B2 (https=)
KR (1) KR20210031435A (https=)
CN (1) CN112512524A (https=)
AU (1) AU2019283649A1 (https=)
BR (1) BR112020024917A2 (https=)
CA (1) CA3102407A1 (https=)
CL (1) CL2020003162A1 (https=)
EA (1) EA202092953A1 (https=)
IL (1) IL279183A (https=)
MX (1) MX2020013181A (https=)
SG (1) SG11202012045UA (https=)
WO (1) WO2019234689A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
FI3801515T3 (fi) 2018-06-06 2025-05-27 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hydroksietyyli)pyridin-2-yyli]etoksi]fenyyli]metyyli]-1,3-tiatsolidiini-2,4-dionia ja sen suoloja käytettäviksi mitokondriosairauksien hoidossa
EP4642456A1 (en) 2022-12-28 2025-11-05 Minoryx Therapeutics S.L. Optimized dosing of leriglitazone
MX2025013233A (es) 2023-05-09 2026-02-03 Minoryx Therapeutics S L Formas polimorficas y formulaciones de leriglitazona

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106470991A (zh) * 2014-04-02 2017-03-01 米尼奥尔克斯治疗有限公司 在中枢神经系统障碍治疗中的2,4‑噻唑烷二酮衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3703058A1 (en) * 2005-11-29 2020-09-02 Children's Hospital Medical Center A method of selecting a medication for a patient
US20140114676A1 (en) * 2012-10-23 2014-04-24 Theranos, Inc. Drug Monitoring and Regulation Systems and Methods
EP3559010B1 (en) 2016-12-23 2022-06-08 Minoryx Therapeutics S.L. Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106470991A (zh) * 2014-04-02 2017-03-01 米尼奥尔克斯治疗有限公司 在中枢神经系统障碍治疗中的2,4‑噻唑烷二酮衍生物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
M.KAWAGUCHI-SUZUKI等: "Concentration-dependent response to pioglitazone in nonalcoholic steatohepatitis", vol. 46, no. 1, pages 1 - 2 *
R.F.FERNANDEZ等: "Peroxisome Proliferator-activated Receptor (PPAR)γAgonism Facilitates Timely Resolution of Acute Sterile Inflammation in Chronic Granulomatous Disease(CGD)", 《J ALLERGY CLIN IMMUNOL》, vol. 125, no. 2, pages 56 *
任润建等: "过氧化物酶体增殖物激活受体γ在炎症相关疾病中作用的研究进展", 《检验医学》, vol. 32, no. 2, pages 153 - 157 *
姜鹏等: "过氧化物酶增殖体激活受体与炎症及免疫反应", 《生命的化学》, vol. 25, no. 3, pages 232 - 235 *
张文旭等: "过氧化物酶体增殖剂激活受体γ的结构特征和生物学功能", 《动物营养学报》, vol. 24, no. 9, pages 1628 - 1635 *
王丽莉等: "PPAR-γ与甲状腺疾病", 《医学综述》, vol. 16, no. 2, pages 164 - 166 *
王玉霞等: "PPARγ与多囊卵巢综合征胰岛素抵抗的研究", 《国外医学妇幼保健分册》, vol. 15, no. 3, pages 185 - 187 *
鲁晓杰等: "垂体腺瘤中过氧化物酶体增殖因子活化受体γ的表达及意义", 《中华神经医学杂志》, vol. 5, no. 12, pages 1223 - 1225 *

Also Published As

Publication number Publication date
WO2019234689A1 (en) 2019-12-12
BR112020024917A2 (pt) 2021-03-09
CL2020003162A1 (es) 2021-07-02
EA202092953A1 (ru) 2021-04-12
MX2020013181A (es) 2021-02-26
IL279183A (en) 2021-01-31
AU2019283649A1 (en) 2021-01-07
CA3102407A1 (en) 2019-12-12
SG11202012045UA (en) 2021-01-28
EP3801516A1 (en) 2021-04-14
KR20210031435A (ko) 2021-03-19
JP7549344B2 (ja) 2024-09-11
JP2021527045A (ja) 2021-10-11
US20210308113A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20240091210A1 (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
CN112512524A (zh) 给予治疗有效量的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮的方法
US20250064791A1 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
EP4309738A2 (en) Method of treating medulloblastoma with an ezh2 inhibitor
US11365215B2 (en) Method for preventing, improving, or treating inflammatory bowel disease
US11938122B2 (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3- thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40049546A (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
EA047277B1 (ru) Способ введения терапевтически эффективного количества 5-[[4-[2-[5-(1-гидроксиэтил)пиридин-2-ил]этокси]фенил]метил]-1,3-тиазолидин-2,4-диона
HK40042762A (en) Use of 5-[[4-[2-[5-acetylpyridin-2-yl]ethoxy]benzyl]-1,3-thiazolidine-2,4-dione and its salts
EA047194B1 (ru) Применение 5-[4-[2-[5-ацетилпиридин-2-ил]этокси]бензил]-1,3-тиазолидин-2,4-диона и его солей
EP4642456A1 (en) Optimized dosing of leriglitazone
HK40014768A (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease
HK40014768B (en) 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]ph-enyl]methyl]-1,3-thiazolidine-2,4-dione for treating nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049546

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210316

WD01 Invention patent application deemed withdrawn after publication